Cara Therapeutics to Announce Q1 2024 Financial Results on May 13

May 06, 2024 – Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company in the development stage, is pioneering a new approach to better the lives of patients suffering from pruritus. The company has announced that it will release its financial results for the first quarter of 2024 on Monday, May 13, 2024, after the U.S. markets close. The report will be accessible in the "Press Releases" section under the Investors tab on the company's website.

Cara Therapeutics is focused on developing innovative solutions for pruritus, particularly through the oral formulation of difelikefalin. This medication is a selective, peripherally acting kappa opioid receptor agonist that is not scheduled as a controlled substance. It aims to treat chronic pruritus associated with notalgia paresthetica (NP), a frequently underdiagnosed neuropathy affecting the upper back, for which there are currently no FDA-approved treatments.

The company is actively conducting a Phase 2/3 clinical trial program for NP. The main objective of this trial is to find an effective dose, with initial results anticipated in the third quarter of 2024. This program represents a significant step in addressing a gap in treatment options for NP patients.

In addition to the oral formulation, Cara Therapeutics has also developed an intravenous (IV) formulation of difelikefalin. This IV formulation has received approval in the United States, the European Union, and several other countries for treating moderate-to-severe pruritus in adults with advanced chronic kidney disease who are on hemodialysis. The global rights for the IV formulation have been out-licensed, allowing broader access to this important treatment.

Cara Therapeutics continues to position itself as a leader in the development of novel therapies for pruritus, working diligently to address the unmet needs of patients with this condition.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!